Treatment Choices for Chronic Lymphocytic Leukemia in Japan
Author Information
Author(s): Yuda Junichiro, Wang Chaochen, Terasawa Tomoko, Tajimi Masaomi, Osaga Satoshi, Miura Moemi, Takaoka Shori, Tanizawa Yoshinori
Primary Institution: National Cancer Center Hospital East
Hypothesis
What factors influence hematologists' treatment decisions for chronic lymphocytic leukemia (CLL) in Japan?
Conclusion
Japanese hematologists often choose treatments based on clinical evidence, but there are variations influenced by their experience and interest in CLL.
Supporting Evidence
- 82.2% of hematologists preferred BTK inhibitors as the first-line treatment for CLL.
- Key factors influencing treatment selection included clinical evidence and patient fitness status.
- Variations in treatment choices were noted based on the hematologists' experience and interest in CLL.
Takeaway
Doctors in Japan mostly pick a specific medicine for a type of blood cancer called CLL based on what they know and how long they've been working.
Methodology
An online survey was conducted among hematologists treating CLL, with responses analyzed descriptively.
Potential Biases
Potential bias due to self-disclosed participant backgrounds and limited exposure to CLL treatment options.
Limitations
The study relied on self-reported data and did not conduct statistical testing for variations in attitudes.
Participant Demographics
The sample included 107 hematologists, with 76.6% being certified specialists and 74.8% having at least 10 years of clinical experience.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website